{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:53:32Z","timestamp":1793069612721,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"19","license":[{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T00:00:00Z","timestamp":1696809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00432-023-05445-z","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T17:01:38Z","timestamp":1696870898000},"page":"17269-17284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The roles of FXYD family members in ovarian cancer: an integrated analysis by mining TCGA and GEO databases and functional validations"],"prefix":"10.1007","volume":"149","author":[{"given":"Eryong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kefei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuelin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"issue":"1","key":"5445_CR1","first-page":"301","volume":"56","author":"Y Bai","year":"2020","unstructured":"Bai Y, Li LD, Li J et al (2020) A FXYD5\/TGFbeta\/SMAD positive feedback loop drives epithelial-to-mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer. Int J Oncol 56(1):301\u2013314","journal-title":"Int J Oncol"},{"key":"5445_CR3","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3389\/fonc.2019.01306","volume":"9","author":"MJ Besso","year":"2019","unstructured":"Besso MJ, Rosso M, Lapyckyj L et al (2019) FXYD5\/Dysadherin, a biomarker of endometrial cancer myometrial invasion and aggressiveness: its relationship with TGF-beta1 and NF-kappaB pathways. Front Oncol 9:1306","journal-title":"Front Oncol"},{"issue":"Pt 2","key":"5445_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.semcancer.2022.03.028","volume":"86","author":"S Bose","year":"2022","unstructured":"Bose S, Saha P, Chatterjee B et al (2022) Chemokines driven ovarian cancer progression, metastasis and chemoresistance: potential pharmacological targets for cancer therapy. Semin Cancer Biol 86(Pt 2):568\u2013579","journal-title":"Semin Cancer Biol"},{"key":"5445_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115\u2013132","journal-title":"CA Cancer J Clin"},{"key":"5445_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-023-00640-9","author":"G Chiosis","year":"2023","unstructured":"Chiosis G, Digwal CS, Trepel JB et al (2023) Structural and functional complexity of HSP90 in cellular homeostasis and disease. Nat Rev Mol Cell Biol. https:\/\/doi.org\/10.1038\/s41580-023-00640-9","journal-title":"Nat Rev Mol Cell Biol"},{"key":"5445_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","volume":"59","author":"MK Ediriweera","year":"2019","unstructured":"Ediriweera MK, Tennekoon KH, Samarakoon SR (2019) Role of the PI3k\/Akt\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance. Semin Cancer Biol 59:147\u2013160","journal-title":"Semin Cancer Biol"},{"key":"5445_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202301865","volume":"2023","author":"L Fan","year":"2023","unstructured":"Fan L, Ma X, Liu B et al (2023) Antioxidant-engineered milk-derived extracellular vesicles for accelerating wound healing via regulation of the PI3K-Akt signaling pathway. Adv Healthc Mater 2023:e2301865","journal-title":"Adv Healthc Mater"},{"issue":"8","key":"5445_CR9","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm.3909","volume":"21","author":"AJ Gentles","year":"2015","unstructured":"Gentles AJ, Newman AM, Liu CL et al (2015) The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med 21(8):938\u2013945","journal-title":"Nat Med"},{"issue":"9951","key":"5445_CR10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC et al (2014) Ovarian cancer. Lancet 384(9951):1376\u20131388","journal-title":"Lancet"},{"issue":"14","key":"5445_CR11","doi-asserted-by":"publisher","first-page":"18404","DOI":"10.18632\/aging.203290","volume":"13","author":"M Jin","year":"2021","unstructured":"Jin M, Zhang H, Yang J et al (2021) Expression mode and prognostic value of FXYD family members in colon cancer. Aging (albany, NY) 13(14):18404\u201318422","journal-title":"Aging (albany, NY)"},{"issue":"4","key":"5445_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR (2018) Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15(4):234\u2013248","journal-title":"Nat Rev Clin Oncol"},{"issue":"16","key":"5445_CR13","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.3390\/cells12162022","volume":"12","author":"D Kamashev","year":"2023","unstructured":"Kamashev D, Shaban N, Lebedev T et al (2023) Human blood serum can diminish EGFR-targeted inhibition of squamous carcinoma cell growth through reactivation of MAPK and EGFR pathways. Cells 12(16):2022","journal-title":"Cells"},{"issue":"1","key":"5445_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ijc.21257","volume":"118","author":"H Kayed","year":"2006","unstructured":"Kayed H, Kleeff J, Kolb A et al (2006) FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer 118(1):43\u201354","journal-title":"Int J Cancer"},{"key":"5445_CR15","doi-asserted-by":"publisher","first-page":"m3773","DOI":"10.1136\/bmj.m3773","volume":"371","author":"L Kuroki","year":"2020","unstructured":"Kuroki L, Guntupalli SR (2020) Treatment of epithelial ovarian cancer. BMJ 371:m3773","journal-title":"BMJ"},{"issue":"6","key":"5445_CR16","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/bioinformatics\/bts034","volume":"28","author":"JT Leek","year":"2012","unstructured":"Leek JT, Johnson WE, Parker HS et al (2012) The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28(6):882\u2013883","journal-title":"Bioinformatics"},{"issue":"4","key":"5445_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM (2019) Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin 69(4):280\u2013304","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5445_CR18","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41392-022-01131-7","volume":"7","author":"GN Li","year":"2022","unstructured":"Li GN, Zhao XJ, Wang Z et al (2022) Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. Signal Transduct Target Ther 7(1):317","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"5445_CR19","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s10549-015-3667-x","volume":"155","author":"CC Liu","year":"2016","unstructured":"Liu CC, Teh R, Mozar CA et al (2016) Silencing overexpression of FXYD3 protein in breast cancer cells amplifies effects of doxorubicin and gamma-radiation on Na(+)\/K(+)-ATPase and cell survival. Breast Cancer Res Treat 155(2):203\u2013213","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"5445_CR20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijrobp.2008.10.076","volume":"75","author":"P Loftas","year":"2009","unstructured":"Loftas P, Onnesjo S, Widegren E et al (2009) Expression of FXYD-3 is an independent prognostic factor in rectal cancer patients with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 75(1):137\u2013142","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"5445_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3857\/roj.2016.34.1.52","volume":"34","author":"P Loftas","year":"2016","unstructured":"Loftas P, Arbman G, Sun XF et al (2016) FXYD-3 expression in relation to local recurrence of rectal cancer. Radiat Oncol J 34(1):52\u201358","journal-title":"Radiat Oncol J"},{"issue":"21","key":"5445_CR22","doi-asserted-by":"publisher","first-page":"11072","DOI":"10.1074\/jbc.M115.699041","volume":"291","author":"I Lubarski-Gotliv","year":"2016","unstructured":"Lubarski-Gotliv I, Asher C, Dada LA et al (2016) FXYD5 protein has a pro-inflammatory role in epithelial cells. J Biol Chem 291(21):11072\u201311082","journal-title":"J Biol Chem"},{"key":"5445_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9986376","volume":"2021","author":"W Luo","year":"2021","unstructured":"Luo W, Liu Q, Chen X et al (2021) FXYD6 regulates chemosensitivity by mediating the expression of Na+\/K+-ATPase alpha1 and affecting cell autophagy and apoptosis in colorectal cancer. Biomed Res Int 2021:9986376","journal-title":"Biomed Res Int"},{"issue":"8","key":"5445_CR24","doi-asserted-by":"publisher","first-page":"4040","DOI":"10.1111\/jcmm.16371","volume":"25","author":"YS Ma","year":"2021","unstructured":"Ma YS, Wu TM, Qian B et al (2021) KDM5A silencing transcriptionally suppresses the FXYD3-PI3K\/Akt axis to inhibit angiogenesis in hepatocellular cancer via mir-433 up-regulation. J Cell Mol Med 25(8):4040\u20134052","journal-title":"J Cell Mol Med"},{"issue":"11","key":"5445_CR25","doi-asserted-by":"publisher","first-page":"9699","DOI":"10.1074\/jbc.M110.184234","volume":"286","author":"NK Mishra","year":"2011","unstructured":"Mishra NK, Peleg Y, Cirri E et al (2011) FXYD proteins stabilize Na, K-ATPase: amplification of specific phosphatidylserine-protein interactions. J Biol Chem 286(11):9699\u20139712","journal-title":"J Biol Chem"},{"issue":"5","key":"5445_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR et al (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12(5):453\u2013457","journal-title":"Nat Methods"},{"issue":"6","key":"5445_CR27","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.2353\/ajpath.2009.080571","volume":"175","author":"K Okudela","year":"2009","unstructured":"Okudela K, Yazawa T, Ishii J et al (2009) Down-regulation of FXYD3 expression in human lung cancers: its mechanism and potential role in carcinogenesis. Am J Pathol 175(6):2646\u20132656","journal-title":"Am J Pathol"},{"issue":"9","key":"5445_CR28","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine E, Ledermann JA, Selle F et al (2017) Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18(9):1274\u20131284","journal-title":"Lancet Oncol"},{"issue":"6","key":"5445_CR29","doi-asserted-by":"publisher","first-page":"5164","DOI":"10.3390\/ijms24065164","volume":"24","author":"S Safe","year":"2023","unstructured":"Safe S (2023) Specificity proteins (SP) and cancer. Int J Mol Sci 24(6):5164","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5445_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"5445_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5445_CR32","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1006\/geno.2000.6274","volume":"68","author":"KJ Sweadner","year":"2000","unstructured":"Sweadner KJ, Rael E (2000) The FXYD gene family of small ion transport regulators or channels: cDNA sequence, protein signature sequence, and expression. Genomics 68(1):41\u201356","journal-title":"Genomics"},{"key":"5445_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2022.175186","volume":"931","author":"XP Tan","year":"2022","unstructured":"Tan XP, Xiong BH, Zhang YX et al (2022) FXYD5 promotes sorafenib resistance through the Akt\/mTOR signaling pathway in hepatocellular carcinoma. Eur J Pharmacol 931:175186","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"5445_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41698-023-00417-5","volume":"7","author":"Z Wang","year":"2023","unstructured":"Wang Z, Muthusamy V, Petrylak DP et al (2023) Tackling FGFR3-driven bladder cancer with a promising synergistic FGFR\/HDAC targeted therapy. NPJ Precis Oncol 7(1):70","journal-title":"NPJ Precis Oncol"},{"key":"5445_CR35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0896","author":"D Xiao","year":"2023","unstructured":"Xiao D, Zeng T, Zhu W et al (2023) ANXA1 promotes tumor immune evasion by binding PARP1 and upregulating Stat3-induced expression of PD-L1 in multiple cancers. Cancer Immunol Res. https:\/\/doi.org\/10.1158\/2326-6066.CIR-22-0896","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"5445_CR36","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41416-020-01158-z","volume":"124","author":"S Yan","year":"2021","unstructured":"Yan S, Xuan J, Brajanovski N et al (2021) The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. Br J Cancer 124(3):616\u2013627","journal-title":"Br J Cancer"},{"issue":"4","key":"5445_CR37","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202012633","volume":"153","author":"JQ Yap","year":"2021","unstructured":"Yap JQ, Seflova J, Sweazey R et al (2021) Fxyd proteins and sodium pump regulatory mechanisms. J Gen Physiol 153(4):e202012633","journal-title":"J Gen Physiol"},{"issue":"15","key":"5445_CR38","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.3390\/cancers14153596","volume":"14","author":"S Yonekura","year":"2022","unstructured":"Yonekura S, Ueda K (2022) FXYD3 expression predicts poor prognosis in renal cell carcinoma with immunosuppressive tumor microenvironment. Cancers (basel) 14(15):3596","journal-title":"Cancers (basel)"},{"issue":"3","key":"5445_CR39","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1155\/2013\/740201","volume":"35","author":"ZL Zhu","year":"2013","unstructured":"Zhu ZL, Yan BY, Zhang Y et al (2013) Overexpression of FXYD-3 is involved in the tumorigenesis and development of esophageal squamous cell carcinoma. Dis Mark 35(3):195\u2013202","journal-title":"Dis Mark"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05445-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05445-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T22:04:57Z","timestamp":1700345097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05445-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":38,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["5445"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05445-z","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}